In 2013, the first 225Ac-labeled PSMA small-molecule ligand PSMA-617 for targeted prostate cancer therapy was developed and investigated at Joint Research Center (JRC) Karlsruhe. The gene discussed is FOLH1; the disease is Familial prostate cancer.